Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its third-quarter 2025 financial results on Wednesday, with total revenue of $4.48 billion, beating analysts' expectations of $4.35 billion, according to Benzinga Pro.Revenues increased 3% year-over-year in U.S. dollars or 1% in local currency.Key brands continue to drive growth, with revenues up 33% in local currency to $830 million.Austedo (Huntington’s disease drug) sales increased 38% to $618 million. Increasing Austedo 2025 revenue outlook to $2. ...